A growing fear: ‘pharmanoia’

People are increasingly wary of taking part in clinical trials, says Cohen Copyright: IDRC / CRDI

Send to a friend

The details you provide on this page will not be used to send unsolicited email, and will not be sold to a 3rd party. See privacy policy.

More and more people, especially in poor countries, are asking what they stand to gain from taking part in clinical trials.

This is only fair, says Jon Cohen in this article, but he deplores the accompanying extreme distrust of drug companies, or ‘pharmanoia’, that he says is detracting attention from more legitimate concerns.

One ethical dilemma that has plagued HIV/AIDS trials is whether or not to give antiretroviral drugs to participants who become HIV positive during — but not because of — the trial.

Over the years, as the price of these drugs has dropped, trial organisers have become more willing to supply them to participants.

This, says Cohen, indicates that some of these research quandaries are more about cost, than issues of right or wrong.

Link to full article on Slate.com